Literature DB >> 26471179

Radiotherapy combined docetaxel and oxaliplatin chemotherapy is effective in patients with locally advanced nasopharyngeal carcinoma.

Feng Pan1, Zhihua Ruan1, Jianjun Li1, Xueli Pang1, Yanling Zhang1, Lan Zou1, Houjie Liang2.   

Abstract

The outcome of locoregionally advanced nasopharyngeal carcinoma (NPC) remains unsatisfactory due to high rates of local and distant failure, and the best way of integration of chemotherapy to chemoradiotherapy was still undefined. The aim of this study was to evaluate the efficacy of radiotherapy combined docetaxel and oxaliplatin (TP) chemotherapy in patients with locally advanced NPC. A total of 62 patients in stages III-IVA with a newly diagnosed and previously untreated NPC were enrolled in this study. All patients received 70-74 Gy in 7 weeks using standard intensity-modulated radiotherapy (IMRT) portals and techniques. A combination of TP chemotherapy were used every 3 weeks for two cycles before and after IMRT. Response analysis including toxicities, efficacy and survival were made 3 months after termination of radiotherapy. No grade 5 toxicity (death) occurred during treatment, and the most common grade 3 hematologic toxicities during chemotherapy were neutropenia (37.1 %), thrombocytopenia (4.8 %) and anemia (4.8 %). The progression free survival rate of 1- , 3- and 5-year were 96.8, 75.8 and 64.5 %, respectively. The overall survival rate of 1- , 3- and 5-year were 100, 82.3 and 75.8 %, respectively. Our findings suggest that induction chemotherapy of TP to IMRT may provide potential improvement of tumor control probability for advanced NPC.

Entities:  

Keywords:  Chemoradiotherapy; Docetaxel; Nasopharyngeal carcinoma; Oxaliplatin

Mesh:

Substances:

Year:  2015        PMID: 26471179     DOI: 10.1007/s12032-015-0698-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

Review 1.  Nasopharyngeal carcinoma: the next challenges.

Authors:  Albiruni R A Razak; Lillian L Siu; Fei-Fei Liu; Emma Ito; Brian O'Sullivan; Kelvin Chan
Journal:  Eur J Cancer       Date:  2010-05-05       Impact factor: 9.162

2.  Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

Authors:  Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

Review 3.  A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma.

Authors:  Daniel T T Chua; Jonathan S T Sham; Gordon K H Au
Journal:  Oral Oncol       Date:  2005-04-14       Impact factor: 5.337

4.  Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.

Authors:  Chengrun Du; Hongmei Ying; Junjun Zhou; Chaosu Hu; Youwang Zhang
Journal:  Int J Clin Oncol       Date:  2012-04-13       Impact factor: 3.402

5.  Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results.

Authors:  Li Zhang; Chong Zhao; Pei-Jian Peng; Li-Xia Lu; Pei-Yu Huang; Fei Han; Shao-Xiong Wu
Journal:  J Clin Oncol       Date:  2005-10-17       Impact factor: 44.544

6.  A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.

Authors:  J S McCarthy; I F Tannock; P Degendorfer; T Panzarella; M Furlan; L L Siu
Journal:  Oral Oncol       Date:  2002-10       Impact factor: 5.337

7.  Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer.

Authors:  J L Oh; E E Vokes; M S Kies; B B Mittal; M E Witt; R R Weichselbaum; D J Haraf
Journal:  Ann Oncol       Date:  2003-04       Impact factor: 32.976

8.  Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience.

Authors:  Anne W M Lee; W M Sze; Joseph S K Au; S F Leung; T W Leung; Daniel T T Chua; Benny C Y Zee; Stephen C K Law; Peter M L Teo; Stewart Y Tung; Dora L W Kwong; W H Lau
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-15       Impact factor: 7.038

9.  Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma.

Authors:  X Wu; P Y Huang; P J Peng; L X Lu; F Han; S X Wu; X Hou; H Y Zhao; Y Huang; W F Fang; Y Y Zhao; C Xue; Z H Hu; J Zhang; J W Zhang; Y X Ma; W H Liang; C Zhao; L Zhang
Journal:  Ann Oncol       Date:  2013-05-09       Impact factor: 32.976

10.  A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).

Authors:  Sewanti Limaye; Sarah Riley; Sihai Zhao; Anne O'Neill; Marshall Posner; Douglas Adkins; Zachary Jaffa; John Clark; Robert Haddad
Journal:  Oral Oncol       Date:  2013-05-30       Impact factor: 5.337

View more
  7 in total

1.  Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.

Authors:  So-Jin Park; Wenda Ye; Roy Xiao; Christopher Silvin; Michelle Padget; James W Hodge; Carter Van Waes; Nicole C Schmitt
Journal:  Oral Oncol       Date:  2019-06-20       Impact factor: 5.337

2.  LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway.

Authors:  Fei Liu; Yong Tai; Jiqing Ma
Journal:  Cancer Biol Ther       Date:  2018-04-09       Impact factor: 4.742

3.  NSUN2 Promotes Tumor Progression and Regulates Immune Infiltration in Nasopharyngeal Carcinoma.

Authors:  Xinya Tong; Yilan Xiang; Yuanbo Hu; Yingying Hu; He Li; Huilin Wang; Kong-Nan Zhao; Xiangyang Xue; Shanli Zhu
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

4.  The Hippocampus Sparing Volume Modulated Arc Therapy does not Influence Plan Quality on Locally Advanced Nasopharyngeal Carcinoma Patients.

Authors:  Wendong Gu; Qilin Li; Dan Xi; Ye Tian; Juncong Mo; Honglei Pei
Journal:  Sci Rep       Date:  2017-06-13       Impact factor: 4.379

5.  CircCTDP1 promotes nasopharyngeal carcinoma progression via a microRNA‑320b/HOXA10/TGFβ2 pathway.

Authors:  Haifeng Li; Jianqiang You; Haixiang Xue; Xiaoye Tan; Changjiang Chao
Journal:  Int J Mol Med       Date:  2020-01-15       Impact factor: 4.101

6.  CircNRIP1 Modulates the miR-515-5p/IL-25 Axis to Control 5-Fu and Cisplatin Resistance in Nasopharyngeal Carcinoma.

Authors:  Junwu Lin; Hong Qin; Yue Han; Xinghua Li; YuJuan Zhao; Guangsheng Zhai
Journal:  Drug Des Devel Ther       Date:  2021-01-27       Impact factor: 4.162

7.  Niclosamide sensitizes nasopharyngeal carcinoma to radiation by downregulating Ku70/80 expression.

Authors:  Jingjing Li; Haiwen Li; Dechao Zhan; Mei Xiang; Jun Yang; Yufang Zuo; Yin Yu; Hechao Zhou; Danxian Jiang; Haiqing Luo; Zihong Chen; Zhonghua Yu; Zumin Xu
Journal:  J Cancer       Date:  2018-02-06       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.